GV20 Therapeutics
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. (NCT07623642) | GV20 Therapeutics | 2026-06-02 |
| Study of GV20-0251 in Participants With Solid Tumor Malignancies (NCT07070518) | GV20 Therapeutics | 2025-07-11 |
| A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies (NCT05669430) | GV20 Therapeutics | 2023-03-23 |
Track GV20 Therapeutics automatically
Every clearance here is in the API, with alerts when new ones post.